AMAG Pharmaceuticals is a pharmaceutical company focused on product candidates across a range of therapeutic areas. Co.'s products support the health of patients in the areas of hematology and maternal and women's health, including Feraheme® (ferumoxytol injection) for intravenous use, Makena® (hydroxyprogesterone caproate injection) auto-injector, Intrarosa® (prasterone) vaginal inserts and Vyleesi® (bremelanotide injection). In addition to its approved products, Co.'s portfolio includes two product candidates, AMAG-423 (digoxin immune fab (ovine)), which is being studied for the treatment of severe preeclampsia, and ciraparantag, which is being studied as an anticoagulant reversal agent. We show 46 historical shares outstanding datapoints in our coverage of AMAG's shares outstanding history.
Understanding the changing numbers of AMAG shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AMAG versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AMAG by allowing them to research AMAG shares outstanding history
as well as any other stock in our coverage universe. |
Free AMAG Email Alerts:
Video: Shares Outstanding Importance
